Oxford BioMedica Announces Positive DSMB Review of Ongoing RetinoStat® and StarGen™ Clinical Studies
— Treatment of final RetinoStat® patient cohort underway — Oxford, UK – 08 August 2012: Oxford BioMedica plc (“Oxford BioMedica”… Read More
Oxford BioMedica Plc Announces Results of Firm Placing and Open Offer
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY… Read More
Oxford BioMedica Receives Funding Award from the Foundation Fighting Blindness for ongoing UshStat® Phase I/IIa study
— Award of US$125,000 will support a second clinical site in Paris, France — Oxford, UK – 23 July 2012: Oxford BioMedica plc… Read More
Oxford BioMedica Announces Initiation of Phase II Collaborative Study for TroVax® in Colorectal Cancer
— First patient treated at Cardiff University, Wales (UK) — Oxford, UK – 10 July 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company,… Read More
Oxford BioMedica Announces Notice of Posting of Prospectus
Click here to view the prospectus NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR… Read More
Oxford BioMedica Announces US$3 million Option Exercise Payment from Sanofi
— Sanofi acquires exclusive worldwide rights to develop and commercialise StarGen™ and UshStat® — Oxford, UK – 29 June… Read More
Oxford BioMedica Announces Proposed Firm Placing of £11 million and Open Offer of up to £5 million
Click here to read the full announcement THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT… Read More
Oxford BioMedica Announces Successful MHRA Inspection for its Proprietary Manufacturing Facility
— MHRA approval received to enable GMP manufacturing for clinical supply — Oxford, UK – 8 June 2012: Oxford BioMedica plc (“Oxford BioMedica”… Read More
Oxford BioMedica Interim Management Statement May 2012
Oxford, UK – 11 May 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period from 1 January to 10 May 2012. Read More
Oxford BioMedica Announces Successful Completion of ProSavin® Phase I/II Study in Parkinson’s Disease
— Study meets primary endpoint: ProSavin® is safe, well-tolerated and mediates long-term improvement of motor function — Oxford, UK – 16 April 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”)… Read More
Oxford BioMedica Announces Successful Completion of ProSavin® Phase I/II Study in Parkinson’s Disease
— Study meets primary endpoint: ProSavin® is safe, well-tolerated and mediates long-term improvement of motor function — Oxford, UK – 16 April 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”)… Read More
Oxford BioMedica Plc Preliminary Results for the Year Ended 31 December 2011
Click here to download the full 2011 preliminary results statement.Click here to download the 2011 results slide deck.Click here to listen to the… Read More